Relationship between beclin1, hif-1α expression levels and the efficacy of trastuzumab in the treatment of HER2-positive breast cancer
10.3760/cma.j.cn115807-20240605-00191
- VernacularTitle:Beclin1、HIF-1 α表达水平与曲妥珠单抗治疗HER2阳性乳腺癌的疗效关系
- Author:
Wen LI
1
;
Qinghe WU
;
Ning LI
Author Information
1. 山东大学齐鲁医院药学部，青岛 266035
- Keywords:
Breast cancer;
Human epidermal growth factor receptor 2;
Hypoxia-induced factor-1 α;
Trastuzumab
- From:
Chinese Journal of Endocrine Surgery
2024;18(5):624-628
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the relationship between the expression levels of beclin1, hypoxia-induced-factor-1 α (HIF-1α) and the efficacy of trastuzumab on human epidermal growth factor receptor 2 (HER2) positive breast cancer.Methods:Clinical data of 90 patients with HER2-positive breast cancer treated with trastuzumab after surgery in our hospital from Mar. 2021 to May. 2023 were collected. The expression levels of Beclin1 and HIF-1α in all patients were determined by immunohistochemistry. Patients were divided into the effective group and the ineffective group according to chemotherapy efficacy. Clinical data and expression levels of Beclin1 and HIF-1α were compared between the two groups, and the relationship between expression levels of Beclin1, HIF-1α and the efficacy was evaluated by Logistic regression analysis.Results:In 90 patients with HER2-positive breast cancer treated with trastuzumab, the effective rate was 72.22% (65/90) and the ineffective rate was 27.78% (25/90). Beclin1 had no expression, low expression and high expression in 11, 26 and 53 HER2-positive breast cancer patients after treatment, which were better than the 23, 29 and 38 cases before treatment; HIF-1α had no expression in 53 cases, low expression in 8 cases and high expression in 29 cases, which was better than that before treatment in 32 cases, 17 cases and 41 cases ( Z=6.50, 7.31, P<0.05). The proportion of TNM stages I-II and histological grade 3 in the effective group was 83.08% (54/65) and 87.69% (57/65), higher than that in the ineffective group [60.00% (15/25) and 64.00% (16/25) ( χ2=5.38, 6.62, P<0.05). The high expression of Beclin1 in the effective group was higher [53.85% (35/65) vs. 12.00% (3/25) ], and the high expression of HIF-1α was lower [36.92% (24/65) vs. 68.00% (17/25) ] ( Z=16.76, 7.59, P<0.05). Logistic regression analysis showed that TNM stage, histological grade, Beclin1 expression level and HIF-1α expression level were all related factors affecting the curative effect of HER2-positive breast cancer patients ( P<0.05) . Conclusions:Beclin1 and HIF-1α expression levels are related to the efficacy of trastuzumab in the treatment of HER2-positive breast cancer, and can be used as a predictor of the efficacy of patients.
